Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients
| Autor: | Geng Wang, Hao-Xian Yang, Mengzhong Liu, Y.-F. Feng, Jing Wen, Kongjia Luo, D.-K. Wang, Yong Hong Hu, Tiehua Rong, Jianhua Fu, Wei Zhao Huang, Bin Zheng |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Esophageal Neoplasms medicine.medical_treatment Cohort Studies Predictive Value of Tests Internal medicine Biopsy medicine Carcinoma Humans Stage (cooking) Survival rate Aged Retrospective Studies medicine.diagnostic_test business.industry Gastroenterology General Medicine Middle Aged medicine.disease Esophagectomy Survival Rate Radiation therapy Treatment Outcome Chemotherapy Adjuvant Cyclooxygenase 2 Carcinoma Squamous Cell Immunohistochemistry Female Radiotherapy Adjuvant business Chemoradiotherapy |
| Zdroj: | Diseases of the Esophagus. 21:679-684 |
| ISSN: | 1442-2050 1120-8694 |
| DOI: | 10.1111/j.1442-2050.2008.00824.x |
| Popis: | Our objective was to investigate whether cyclooxygenase-2 (COX-2) expression can predict the patient's response to chemoradiotherapy (CRT) and ensuing prognosis in esophageal squamous cell carcinoma (ESCC). The clinicopathological and follow-up data of 112 patients with ESCC who underwent CRT from January 2001 to June 2006 were analyzed retrospectively. The immunohistochemical expression level of COX-2 was examined for all biopsy specimens of primary tumors, and the correlation of COX-2 expression with the patient's response to CRT and prognosis was examined. COX-2 positive immunostaining was detected in 111 (99.1%) of the patients, including overexpression in 54 (48.2%) patients and low expression in 58 (51.8%) of the patients. The response of tumors with a low level expression of COX-2 (70.7%, 41/58) was significantly higher than that of tumors with COX-2 overexpression (42.6%, 23/54; P = 0.003). Patients with a low level of COX-2 expression had a higher downstaged rate than those with a high level of COX-2 expression (9/13 vs 2/8), but the difference was not statistically significant (P = 0.08). In the definitive CRT group (91 cases), COX-2 overexpression was significantly associated with poor 3-year overall survival (P = 0.028). Multivariate analysis showed that only metastatic stage (nonregional node metastasis) was an independent prognosis factor. The assessment of COX-2 status may provide additional information to identify ESCC patients with poor chances of response to CRT and potential candidates for more individualized treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|